Eye Therapies, LLC Report issue

For profit Phase 2
Founded: Dana Point CA United States (2010)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2011
NCT01275105
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

brimonidine (alphagan) (3 trials)

oxymetazoline (ocuclear) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Glaucoma (Phase 1)

Glaucoma, Open-Angle (Phase 1)

Hypertension (Phase 1)

Ocular Hypertension (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2